Skip to main content

Advertisement

SpringerLink
Log in

Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer’s disease from bench to bedside

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia and cognitive impairment; yet, there is currently no treatment. A buildup of Aβ, tau protein phosphorylation, oxidative stress, and inflammation in AD is pathogenic. The accumulation of amyloid-beta (Aβ) peptides in these neurocognitive areas is a significant characteristic of the disease. Therefore, inhibiting Aβ peptide aggregation has been proposed as the critical therapeutic approach for AD treatment. Resveratrol has been demonstrated in multiple studies to have a neuroprotective, anti-inflammatory, and antioxidant characteristic and the ability to minimize Aβ peptides aggregation and toxicity in the hippocampus of Alzheimer’s patients, stimulating neurogenesis and inhibiting hippocampal degeneration. Furthermore, resveratrol’s antioxidant effect promotes neuronal development by activating the silent information regulator-1 (SIRT1), which can protect against the detrimental effects of oxidative stress. Resveratrol-induced SIRT1 activation is becoming more crucial in developing novel therapeutic options for AD and other diseases that have neurodegenerative characteristics. This review highlighted a better knowledge of resveratrol’s mechanism of action and its promising therapeutic efficacy in treating AD. We also highlighted the therapeutic potential of resveratrol as an AD therapeutic agent, which is effective against neurodegenerative disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zhao T, Zeng Y, Kermode AR (2012) A plant cell-based system that predicts aβ42 misfolding: potential as a drug discovery tool for Alzheimer’s disease. Mol Genet Metab 107:571–579

    Article  CAS  PubMed  Google Scholar 

  2. Rahman MH, Akter R, Bhattacharya T et al (2020) Resveratrol and neuroprotection: impact and its therapeutic potential in Alzheimer’s disease. Front Pharmacol 11:619024. https://doi.org/10.3389/fphar.2020.619024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yan Y, Yang H, Xie Y et al (2020) Research progress on Alzheimer’s disease and resveratrol. Neurochem Res 45:989–1006

    Article  CAS  PubMed  Google Scholar 

  4. Uddin MS, Kabir MT, Rahman MH et al (2020) Exploring the multifunctional neuroprotective promise of rasagiline derivatives for multi-dysfunctional Alzheimer’s disease. Curr Pharm Des. https://doi.org/10.2174/1381612826666200406075044

    Article  PubMed  Google Scholar 

  5. Zhang B, Yin X, Sui S (2018) Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3-kinase/protein kinase B pathway. Oncol Rep 40:2758–2765

    CAS  PubMed  Google Scholar 

  6. Jiao Y, Li H, Liu Y et al (2015) Resveratrol inhibits the invasion of glioblastoma-initiating cells via down-regulation of the PI3K/Akt/NF-κB signaling pathway. Nutrients 7:4383–4402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Feng Y-L, Jiang X-T, Ma F-F et al (2018) Resveratrol prevents osteoporosis by upregulating FoxO1 transcriptional activity. Int J Mol Med 41:202–212

    CAS  PubMed  Google Scholar 

  8. Rahman MH, Akter R, Kamal MA (2020) Prospective function of different antioxidant containing natural products in the treatment of neurodegenerative disease. CNS Neurol Disord - Drug Targets. https://doi.org/10.2174/1871527319666200722153611

    Article  Google Scholar 

  9. Xu P, Zhang M, Sheng R, Ma Y (2017) Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ1–42 aggregation inhibitors and metal-chelating agents for Alzheimer’s disease. Eur J Med Chem 127:174–186

    Article  CAS  PubMed  Google Scholar 

  10. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608. https://doi.org/10.15252/emmm.201606210

  11. Cao J, Hou J, Ping J, Cai D (2018) Advances in developing novel therapeutic strategies for Alzheimer’s disease. Mol Neurodegener 13:1–20

    Article  CAS  Google Scholar 

  12. Corriveau RA, Koroshetz WJ, Gladman JT et al (2017) Alzheimer’s disease–related dementias summit 2016: National research priorities. Neurology 89:2381–2391

    Article  PubMed  PubMed Central  Google Scholar 

  13. Colin J, Allouche A, Chauveau F et al (2016) Improved neuroprotection provided by drug combination in neurons exposed to cell-derived soluble amyloid-β peptide. J Alzheimer’s Dis 52:975–987

    Article  CAS  Google Scholar 

  14. Rao YL, Ganaraja B, Joy T et al (2020) Neuroprotective effects of resveratrol in Alzheimer’s disease. Front Biosci 12:130–149

    Google Scholar 

  15. Wightman EL (2017) Potential benefits of phytochemicals against Alzheimer’s disease. Proc Nutr Soc 76:106–112

    Article  PubMed  Google Scholar 

  16. Virmani A, Pinto L, Binienda Z, Ali S (2013) Food, nutrigenomics, and neurodegeneration—neuroprotection by what you eat! Mol Neurobiol 48:353–362

    Article  CAS  PubMed  Google Scholar 

  17. Bellozi PMQ, de Assis Lima IV, Dória JG et al (2016) Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1–42 induced neurotoxicity and memory impairment. Sci Rep 6:1–12

    Article  CAS  Google Scholar 

  18. Wąsik A, Antkiewicz-Michaluk L (2017) The mechanism of neuroprotective action of natural compounds. Pharmacol Reports 69:851–860

    Article  CAS  Google Scholar 

  19. Kaur D, Behl T, Sehgal A, et al (2021) Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer’s disease. Metab Brain Dis 1–16

  20. Rahman MA, Hannan MA, Dash R, et al (2021) Phytochemicals as a complement to cancer chemotherapy: pharmacological modulation of the autophagy-apoptosis pathway. Front. Pharmacol. 12

  21. Shah SAA, Ul Hassan SS, Bungau S, et al (2020) Chemically diverse and biologically active secondary metabolites from marine phylum chlorophyta. Mar. Drugs 18

  22. Bagli E, Goussia A, Moschos MM et al (2016) Natural compounds and neuroprotection: mechanisms of action and novel delivery systems. In Vivo (Brooklyn) 30:535–547

    CAS  Google Scholar 

  23. Pohl F, Lin PKT (2018) The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: in vitro, in vivo and clinical trials. Molecules 23:3283. https://doi.org/10.3390/molecules23123283

    Article  CAS  PubMed Central  Google Scholar 

  24. Habtemariam S (2019) Natural products in Alzheimer’s disease therapy: would old therapeutic approaches fix the broken promise of modern medicines? Molecules 24:1519

    Article  CAS  PubMed Central  Google Scholar 

  25. Zhang H, Bai L, He J et al (2017) Recent advances in discovery and development of natural products as source for anti-Parkinson’s disease lead compounds. Eur J Med Chem 141:257–272

    Article  CAS  PubMed  Google Scholar 

  26. X Rong L Jiang M Qu et al 2020 Enhancing therapeutic efficacy of donepezil by combined therapy: a comprehensive review Curr Pharm Des 27. https://doi.org/10.2174/1381612826666201023144836

  27. Beesley S, Olcese J, Saunders C, Bienkiewicz EA (2017) Combinatorial treatment effects in a cell culture model of Alzheimer’s disease. J Alzheimer’s Dis 55:1155–1166

    Article  CAS  Google Scholar 

  28. Mancuso C, Bates TE, Butterfield DA et al (2007) Natural antioxidants in Alzheimer’s disease. Expert Opin Investig Drugs 16:1921–1931

    Article  CAS  PubMed  Google Scholar 

  29. Mattson MP, Son TG, Camandola S (2007) Mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose-Response 5:dose-response

  30. D’Angelo S, Mele E, Di Filippo F et al (2021) Sirt1 activity in the brain: Simultaneous effects on energy homeostasis and reproduction. Int J Environ Res Public Health 18:1243

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Zhou D-D, Luo M, Huang S-Y, et al (2021) Effects and mechanisms of resveratrol on aging and age-related diseases. Oxid Med Cell Longev 2021:

  32. Li F, Gong Q, Dong H, Shi J (2012) Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des 18:27–33

    Article  PubMed  Google Scholar 

  33. Huang Y, Lu J, Zhan L, et al (2021) Resveratrol-induced Sirt1 phosphorylation by LKB1 mediates mitochondrial metabolism. J Biol Chem 297:

  34. Sanders HM, Jovcevski B, Marty MT, Pukala TL (2022) Structural and mechanistic insights into amyloid-β and α-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers. FEBS J 289:215–230

    Article  CAS  PubMed  Google Scholar 

  35. Kanazirska V, M, M Fuchs P, Chen L, et al (2012) Beneficial effects of lysosome-modulating and other pharmacological and nanocarrier agents on amyloid-beta-treated cells. Curr Pharm Biotechnol 13:2761–2767

    Article  CAS  PubMed  Google Scholar 

  36. Oomen CA, Farkas E, Roman V et al (2009) Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front Aging Neurosci 1:4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Holland N, Bolognesi C, Kirsch-Volders M et al (2008) The micronucleus assay in human buccal cells as a tool for biomonitoring DNA damage: the HUMN project perspective on current status and knowledge gaps. Mutat Res Mutat Res 659:93–108

    Article  CAS  PubMed  Google Scholar 

  38. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506

    Article  CAS  PubMed  Google Scholar 

  39. Yepes-Nuñez JJ, Urrútia G, Romero-García M, Alonso-Fernández S (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol 74:790–799. https://doi.org/10.1016/j.recesp.2021.06.016

    Article  Google Scholar 

  40. Page MJ, McKenzie JE, Bossuyt PM et al (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103–112. https://doi.org/10.1016/j.jclinepi.2021.02.003

    Article  PubMed  Google Scholar 

  41. Ahmed T, Javed S, Javed S et al (2017) Resveratrol and Alzheimer’s disease: mechanistic insights. Mol Neurobiol 54:2622–2635

    Article  CAS  PubMed  Google Scholar 

  42. Chong J, Poutaraud A, Hugueney P (2009) Metabolism and roles of stilbenes in plants. Plant Sci 177:143–155

    Article  CAS  Google Scholar 

  43. Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z (2003) Glycosylation of resveratrol protects it from enzymic oxidation. Biochem J 374:157–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Gachon CMM, Langlois-Meurinne M, Saindrenan P (2005) Plant secondary metabolism glycosyltransferases: the emerging functional analysis. Trends Plant Sci 10:542–549

    Article  CAS  PubMed  Google Scholar 

  45. Zhang L, Cui L, Zhou G et al (2013) Pterostilbene, a natural small-molecular compound, promotes cytoprotective macroautophagy in vascular endothelial cells. J Nutr Biochem 24:903–911

    Article  CAS  PubMed  Google Scholar 

  46. Schmidlin L, Poutaraud A, Claudel P et al (2008) A stress-inducible resveratrol O-methyltransferase involved in the biosynthesis of pterostilbene in grapevine. Plant Physiol 148:1630–1639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ball JM, Medina-Bolivar F, Defrates K, et al (2015) Investigation of stilbenoids as potential therapeutic agents for rotavirus gastroenteritis. Adv Virol 2015:

  48. Keylor MH, Matsuura BS, Stephenson CRJ (2015) Chemistry and biology of resveratrol-derived natural products. Chem Rev 115:8976–9027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Vingtdeux V, Dreses-Werringloer U, Zhao H et al (2008) Therapeutic potential of resveratrol in Alzheimer’s disease. BMC Neurosci 9:1–5

    Article  CAS  Google Scholar 

  50. Filardo S, Di Pietro M, Mastromarino P, Sessa R (2020) Therapeutic potential of resveratrol against emerging respiratory viral infections. Pharmacol Ther 214:107613

    Article  CAS  PubMed  Google Scholar 

  51. Briskey D, Rao A (2020) Trans-Resveratrol oral bioavailability in humans using LipiSperse™ Dispersion Technology. Pharmaceutics 12:1190

    Article  CAS  PubMed Central  Google Scholar 

  52. Landau D, Haghiac M, Minium J et al (2019) Activation of AMPK in human placental explants impairs mitochondrial function and cellular metabolism. Reprod Sci 26:487–495

    Article  CAS  PubMed  Google Scholar 

  53. Park S-J, Ahmad F, Philp A et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421–433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Price NL, Gomes AP, Ling AJY et al (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kabir MT, Rahman MH, Akter R, et al (2021) Potential role of curcumin and its nanoformulations to treat various types of cancers. Biomolecules 11

  56. Malhotra A, Bath S, Elbarbry F (2015) An organ system approach to explore the antioxidative, anti-inflammatory, and cytoprotective actions of resveratrol. Oxid Med Cell Longev 2015:803971. https://doi.org/10.1155/2015/803971

    Article  PubMed  PubMed Central  Google Scholar 

  57. Frozza RL, Bernardi A, Paese K et al (2010) Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol 6:694–703. https://doi.org/10.1166/jbn.2010.1161

    Article  CAS  PubMed  Google Scholar 

  58. AY Berman RA Motechin MY Wiesenfeld MK Holz 2017 The therapeutic potential of resveratrol: a review of clinical trials NPJ Precis Oncol 1. https://doi.org/10.1038/s41698-017-0038-6

  59. Islam MR, Islam F, Nafady MH, et al Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint. Molecules 27;27(7):2:

  60. Mitra S, Anjum J, Muni M et al (2022) Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action. Biomed Pharmacother 149:112877

    Article  CAS  PubMed  Google Scholar 

  61. Puca AA, Carrizzo A, Villa F et al (2013) Vascular ageing: the role of oxidative stress. Int J Biochem Cell Biol 45:556–559. https://doi.org/10.1016/j.biocel.2012.12.024

    Article  CAS  PubMed  Google Scholar 

  62. Kuršvietienė L, Stanevičienė I, Mongirdienė A, Bernatonienė J (2016) Multiplicity of effects and health benefits of resveratrol. Medicina (Kaunas) 52:148–155. https://doi.org/10.1016/j.medici.2016.03.003

    Article  Google Scholar 

  63. Islam F, Mitra S, Nafady MH, et al Neuropharmacological and antidiabetic potential of Lannea coromandelica (Houtt.) Merr. leaves extract: an experimental analysis. Evidence-Based Complement Altern Med

  64. Feng Y-S, Tan Z-X, Wu L-Y et al (2021) The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases. Biomed Pharmacother 138:111428. https://doi.org/10.1016/j.biopha.2021.111428

    Article  CAS  PubMed  Google Scholar 

  65. IS You S Sharma A Fadriquela et al 2021 Antioxidant properties of hydrogen gas attenuates oxidative stress in airway epithelial cells Molecules 26. https://doi.org/10.3390/molecules26216375

  66. Kaushik D, Goel E, Verma R, et al (2021) An overview of recent patents and patented technology platforms based on co-processed excipients. Recent Adv. Drug Deliv. Formul. 15

  67. Trinh TT, Fadriquela A, Lee KJ, et al (2021) Development of alkaline reduced water using high-temperature-roasted mineral salt and its antioxidative effect in raw 264.7 murine macrophage cell line. Processes 9:. https://doi.org/10.3390/pr9111928

  68. Palacino JJ, Sagi D, Goldberg MS et al (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279:18614–18622. https://doi.org/10.1074/jbc.M401135200

    Article  CAS  PubMed  Google Scholar 

  69. Wang H, Jiang T, Li W et al (2018) Resveratrol attenuates oxidative damage through activating mitophagy in an in vitro model of Alzheimer’s disease. Toxicol Lett 282:100–108. https://doi.org/10.1016/j.toxlet.2017.10.021

    Article  CAS  PubMed  Google Scholar 

  70. Tabner BJ, El-Agnaf OMA, Turnbull S et al (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem 280:35789–35792. https://doi.org/10.1074/jbc.C500238200

    Article  CAS  PubMed  Google Scholar 

  71. Lu C, Guo Y, Li J et al (2012) Design, synthesis, and evaluation of resveratrol derivatives as Aß(1-42) aggregation inhibitors, antioxidants, and neuroprotective agents. Bioorg Med Chem Lett 22:7683–7687. https://doi.org/10.1016/j.bmcl.2012.09.105

    Article  CAS  PubMed  Google Scholar 

  72. Reddy PH, Tripathi R, Troung Q et al (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822:639–649. https://doi.org/10.1016/j.bbadis.2011.10.011

    Article  CAS  PubMed  Google Scholar 

  73. Reddy PH, Tonk S, Kumar S et al (2017) A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer’s disease. Biochem Biophys Res Commun 483:1156–1165. https://doi.org/10.1016/j.bbrc.2016.08.067

    Article  CAS  PubMed  Google Scholar 

  74. Espay AJ, Kalia LV, Gan-Or Z et al (2020) Disease modification and biomarker development in Parkinson disease: revision or reconstruction? Neurology 94:481–494. https://doi.org/10.1212/WNL.0000000000009107

    Article  PubMed  PubMed Central  Google Scholar 

  75. Wu F, Mattson MP, Yao PJ (2010) Neuronal activity and the expression of clathrin-assembly protein AP180. Biochem Biophys Res Commun 402:297–300. https://doi.org/10.1016/j.bbrc.2010.10.018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Zhang F, Zhong R-J, Cheng C et al (2021) New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease. Acta Pharmacol Sin 42:1382–1389. https://doi.org/10.1038/s41401-020-00565-5

    Article  CAS  PubMed  Google Scholar 

  77. T Bhattacharya PS Dey R Akter et al 2021 Effect of natural leaf extracts as phytomedicine in curing geriatrics Exp Gerontol 150. https://doi.org/10.1016/j.exger.2021.111352

  78. Ge J-F, Qiao J-P, Qi C-C et al (2012) The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int 61:1192–1201. https://doi.org/10.1016/j.neuint.2012.08.012

    Article  CAS  PubMed  Google Scholar 

  79. Saleem U, Sabir S, Niazi SG et al (2020) Role of oxidative stress and antioxidant defense biomarkers in neurodegenerative diseases. Crit Rev Eukaryot Gene Expr 30:311–322. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020029202

    Article  PubMed  Google Scholar 

  80. Hung CH-L, Ho Y-S, Chang RC-C (2010) Modulation of mitochondrial calcium as a pharmacological target for Alzheimer’s disease. Ageing Res Rev 9:447–456. https://doi.org/10.1016/j.arr.2010.05.003

    Article  CAS  PubMed  Google Scholar 

  81. Shi D, Yang J, Jiang Y et al (2020) The antioxidant activity and neuroprotective mechanism of isoliquiritigenin. Free Radic Biol Med 152:207–215. https://doi.org/10.1016/j.freeradbiomed.2020.03.016

    Article  CAS  PubMed  Google Scholar 

  82. Stanyon HF, Viles JH (2012) Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: implications for Alzheimer disease. J Biol Chem 287:28163–28168. https://doi.org/10.1074/jbc.C112.360800

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Kumar R, Chaterjee P, Sharma PK et al (2013) Sirtuin1: a promising serum protein marker for early detection of Alzheimer’s disease. PLoS ONE 8:e61560. https://doi.org/10.1371/journal.pone.0061560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Julien C, Tremblay C, Emond V et al (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68:48–58. https://doi.org/10.1097/NEN.0b013e3181922348

    Article  CAS  PubMed  Google Scholar 

  85. Koo J-H, Kang E-B, Oh Y-S et al (2017) Treadmill exercise decreases amyloid-β burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer’s disease. Exp Neurol 288:142–152. https://doi.org/10.1016/j.expneurol.2016.11.014

    Article  CAS  PubMed  Google Scholar 

  86. Marwarha G, Raza S, Meiers C, Ghribi O (2014) Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim Biophys Acta 1842:1587–1595. https://doi.org/10.1016/j.bbadis.2014.05.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Kumar R, Nigam L, Singh AP et al (2017) Design, synthesis of allosteric peptide activator for human SIRT1 and its biological evaluation in cellular model of Alzheimer’s disease. Eur J Med Chem 127:909–916. https://doi.org/10.1016/j.ejmech.2016.11.001

    Article  CAS  PubMed  Google Scholar 

  88. Guarente L (2013) Calorie restriction and sirtuins revisited. Genes Dev 27:2072–2085. https://doi.org/10.1101/gad.227439.113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Satoh A, Imai S (2014) Hypothalamic Sirt1 in aging. Aging (Albany. NY). 6:1–2

  90. Michán S, Li Y, Chou MM-H et al (2010) SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci 30:9695–9707. https://doi.org/10.1523/JNEUROSCI.0027-10.2010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Puig-Parnau I, Garcia-Brito S, Faghihi N et al (2020) Intracranial self-stimulation modulates levels of SIRT1 protein and neural plasticity-related microRNAs. Mol Neurobiol 57:2551–2562. https://doi.org/10.1007/s12035-020-01901-w

    Article  CAS  PubMed  Google Scholar 

  92. Li X, Feng Y, Wang X-X, et al (2020) The critical role of SIRT1 in Parkinson’s disease: mechanism and therapeutic considerations. Aging Dis 11:1608–1622. https://doi.org/10.14336/AD.2020.0216

  93. Bernier M, Paul RK, Martin-Montalvo A et al (2011) Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J Biol Chem 286:19270–19279. https://doi.org/10.1074/jbc.M110.200311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Ramis MR, Esteban S, Miralles A et al (2015) Caloric restriction, resveratrol and melatonin: role of SIRT1 and implications for aging and related-diseases. Mech Ageing Dev 146–148:28–41. https://doi.org/10.1016/j.mad.2015.03.008

    Article  CAS  PubMed  Google Scholar 

  95. Karthika C, Hari B, Mano V, et al (2021) Curcumin as a great contributor for the treatment and mitigation of colorectal cancer. Exp. Gerontol. 152

  96. Karthika C, Hari B, Rahman MH, et al (2021) Multiple strategies with the synergistic approach for addressing colorectal cancer. Biomed. Pharmacother. 140

  97. Wang J, Fivecoat H, Ho L et al (2010) The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer’s disease neuropathology. Biochim Biophys Acta 1804:1690–1694. https://doi.org/10.1016/j.bbapap.2009.11.015

    Article  CAS  PubMed  Google Scholar 

  98. Li S-Y, Wang X-B, Kong L-Y (2014) Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer’s disease. Eur J Med Chem 71:36–45. https://doi.org/10.1016/j.ejmech.2013.10.068

    Article  CAS  PubMed  Google Scholar 

  99. Gomes BAQ, Silva JPB, Romeiro CFR et al (2018) Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: role of SIRT1. Oxid Med Cell Longev 2018:8152373. https://doi.org/10.1155/2018/8152373

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Yang Y, Jiang S, Dong Y et al (2015) Melatonin prevents cell death and mitochondrial dysfunction via a SIRT 1-dependent mechanism during ischemic-stroke in mice. J Pineal Res 58:61–70

    Article  CAS  PubMed  Google Scholar 

  101. Ding M, Feng NA, Tang D et al (2018) Melatonin prevents D rp1-mediated mitochondrial fission in diabetic hearts through SIRT 1-PGC 1α pathway. J Pineal Res 65:e12491

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Supinski GS, Schroder EA, Callahan LA (2020) Mitochondria and critical illness. Chest 157:310–322

    Article  CAS  PubMed  Google Scholar 

  103. Yang X, Si P, Qin H, et al (2017) The neuroprotective effects of SIRT1 on NMDA-induced excitotoxicity. Oxid Med Cell Longev 2017:

  104. Sadi G, Konat D (2016) Resveratrol regulates oxidative biomarkers and antioxidant enzymes in the brain of streptozotocin-induced diabetic rats. Pharm Biol 54:1156–1163. https://doi.org/10.3109/13880209.2015.1056311

    Article  CAS  PubMed  Google Scholar 

  105. Y Huo D Yang K Lai et al 2021 Antioxidant effects of resveratrol in intervertebral disk J Investig Surg Off J Acad Surg Res 1–10. https://doi.org/10.1080/08941939.2021.1988771

  106. Yang X, Qiang X, Li Y et al (2017) Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer’s disease. Bioorg Chem 71:305–314. https://doi.org/10.1016/j.bioorg.2017.02.016

    Article  CAS  PubMed  Google Scholar 

  107. Schweiger S, Matthes F, Posey K et al (2017) Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. Sci Rep 7:13753. https://doi.org/10.1038/s41598-017-12974-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Rege SD, Geetha T, Broderick TL, Babu JR (2015) Resveratrol protects β amyloid-induced oxidative damage and memory associated proteins in H19–7 hippocampal neuronal cells. Curr Alzheimer Res 12:147–156. https://doi.org/10.2174/1567205012666150204130009

    Article  CAS  PubMed  Google Scholar 

  109. Wang X-Q, Zhou L-Y, Tan R-X et al (2021) Design, synthesis, and evaluation of chalcone derivatives as multifunctional agents against Alzheimer’s disease. Chem Biodivers 18:e2100341. https://doi.org/10.1002/cbdv.202100341

    Article  CAS  PubMed  Google Scholar 

  110. Villaflores OB, Chen Y-J, Chen C-P et al (2012) Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwan J Obstet Gynecol 51:515–525. https://doi.org/10.1016/j.tjog.2012.09.005

    Article  PubMed  Google Scholar 

  111. Ma X, Sun Z, Han X et al (2019) Neuroprotective effect of resveratrol via activation of Sirt1 Signaling in a rat model of combined diabetes and Alzheimer’s disease. Front Neurosci 13:1400. https://doi.org/10.3389/fnins.2019.01400

    Article  PubMed  Google Scholar 

  112. Rahman M, Majumder S, Akter F, et al (2021) Pre-clinical investigation of analgesic, anti-diarrheal and CNS depressant effect of Pterocarpus indicus in Swiss albino mice. Jordan J Pharm Sci 14:

  113. Chen J-Y, Zhu Q, Zhang S et al (2019) Resveratrol in experimental Alzheimer’s disease models: a systematic review of preclinical studies. Pharmacol Res 150:104476. https://doi.org/10.1016/j.phrs.2019.104476

    Article  CAS  PubMed  Google Scholar 

  114. Karuppagounder SS, Pinto JT, Xu H et al (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 54:111–118

    Article  CAS  PubMed  Google Scholar 

  115. Vingtdeux V, Giliberto L, Zhao H et al (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-β peptide metabolism. J Biol Chem 285:9100–9113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Porquet D, Casadesús G, Bayod S et al (2013) Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8. Age (Omaha) 35:1851–1865

    Article  CAS  Google Scholar 

  117. Du L-L, Xie J-Z, Cheng X-S et al (2014) Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Omaha) 36:613–623

    Article  CAS  Google Scholar 

  118. Gong Q-H, Li F, Jin F, Shi J-S (2010) Resveratrol attenuates neuroinflammation-mediated cognitive deficits in rats. J Heal Sci 56:655–663

    Article  CAS  Google Scholar 

  119. Zhao H, Niu Q, Li X et al (2012) Long-term resveratrol consumption protects ovariectomized rats chronically treated with D-galactose from developing memory decline without effects on the uterus. Brain Res 1467:67–80

    Article  CAS  PubMed  Google Scholar 

  120. Wang G, Chen L, Pan X et al (2016) The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Oncotarget 7:17380

    Article  PubMed  PubMed Central  Google Scholar 

  121. Molina-Holgado F, Hider RC, Gaeta A et al (2007) Metals ions and neurodegeneration. Biometals 20:639–654

    Article  CAS  PubMed  Google Scholar 

  122. Bishop GM, Robinson SR, Liu Q et al (2002) Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 24:184–187

    Article  CAS  PubMed  Google Scholar 

  123. Huang X, Atwood CS, Moir RD et al (1997) Zinc-induced Alzheimer’s Aβ1–40 aggregation is mediated by conformational factors. J Biol Chem 272:26464–26470

    Article  CAS  PubMed  Google Scholar 

  124. Rao KSJ, Rao RV, Shanmugavelu P, Menon RB (1999) Trace elements in Alzheimer’s disease brain: a new hypothesis. Alzheimers Rep 2:241–246

    Google Scholar 

  125. Kalia K, Flora SJS (2005) Strategies for safe and effective therapeutic measures for chronic arsenic and lead poisoning. J Occup Health 47:1–21

    Article  CAS  PubMed  Google Scholar 

  126. Andersen O (2004) Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem 4:11–21

    Article  CAS  PubMed  Google Scholar 

  127. Knudtson ML, Wyse DG, Galbraith PD et al (2002) Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA 287:481–486

    Article  CAS  PubMed  Google Scholar 

  128. Clarke CN, Clarke NE, Mosher RE (1956) Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 232:654–666

    Article  CAS  PubMed  Google Scholar 

  129. Fonseca-Santos B, Chorilli M (2020) The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. Int J Pharm 589:119832. https://doi.org/10.1016/j.ijpharm.2020.119832

    Article  CAS  PubMed  Google Scholar 

  130. de Vrij FMS, Fischer DF, van Leeuwen FW, Hol EM (2004) Protein quality control in Alzheimer’s disease by the ubiquitin proteasome system. Prog Neurobiol 74:249–270. https://doi.org/10.1016/j.pneurobio.2004.10.001

    Article  CAS  PubMed  Google Scholar 

  131. Song S, Kim S-Y, Hong Y-M et al (2003) Essential role of E2–25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell 12:553–563. https://doi.org/10.1016/j.molcel.2003.08.005

    Article  CAS  PubMed  Google Scholar 

  132. Kriem B, Sponne I, Fifre A et al (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J Off Publ Fed Am Soc Exp Biol 19:85–87. https://doi.org/10.1096/fj.04-1807fje

    Article  CAS  Google Scholar 

  133. Chalimoniuk M, Głowacka J, Zabielna A et al (2006) Nitric oxide alters arachidonic acid turnover in brain cortex synaptoneurosomes. Neurochem Int 48:1–8. https://doi.org/10.1016/j.neuint.2005.08.011

    Article  CAS  PubMed  Google Scholar 

  134. Guedj A, Volman Y, Geiger-Maor A et al (2020) Gut microbiota shape “inflamm-ageing” cytokines and account for age-dependent decline in DNA damage repair. Gut 69:1064–1075. https://doi.org/10.1136/gutjnl-2019-318491

    Article  CAS  PubMed  Google Scholar 

  135. Patel P, Lockey RF, Kolliputi N (2015) Can inflammation regulate systemic aging? Exp Gerontol 67:1–2. https://doi.org/10.1016/j.exger.2015.04.011

    Article  PubMed  Google Scholar 

  136. Sierra A, Gottfried-Blackmore AC, Mcewen BS, Bulloch K (2007) Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 55:412–424. https://doi.org/10.1002/glia.20468

    Article  PubMed  Google Scholar 

  137. Cataldi R, Chia S, Pisani K et al (2021) A dopamine metabolite stabilizes neurotoxic amyloid-β oligomers. Commun Biol 4:19. https://doi.org/10.1038/s42003-020-01490-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Walia V, Kaushik D, Mittal V, et al (2021) Delineation of neuroprotective effects and possible benefits of antioxidantstherapy for the treatment of Alzheimer’s diseases by targeting mitochondrial-derived reactive oxygen species: bench to bedside. Mol. Neurobiol.

  139. J Bajgai K-J Lee MH Rahman et al 2020 Role of molecular hydrogen in skin diseases and its impact in beauty Curr Pharm Des 27https://doi.org/10.2174/1381612826666200925124235

  140. T Tsukahara H Haniu T Uemura Y Matsuda 2020 Therapeutic potential of porcine liver decomposition product: new insights and perspectives for microglia-mediated neuroinflammation in neurodegenerative diseases Biomedicines 8https://doi.org/10.3390/biomedicines8110446

  141. RAUF A, BAWAZEER S, RAZA M, et al (2021) Reversal of multidrug resistance and antitumor promoting activity of 3-oxo-6β-hydroxy- β-amyrin isolated from Pistacia integerrima. Biocell 45:. https://doi.org/10.32604/BIOCELL.2021.013277

  142. Renaud J, Bournival J, Zottig X, Martinoli M-G (2014) Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: effect on p53 and GRP75 localization. Neurotox Res 25:110–123. https://doi.org/10.1007/s12640-013-9439-7

    Article  CAS  PubMed  Google Scholar 

  143. Yang Y, Hu L, Xia Y et al (2016) Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. J Neuroinflammation 13:84. https://doi.org/10.1186/s12974-016-0550-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Jang J-H, Surh Y-J (2003) Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 34:1100–1110. https://doi.org/10.1016/s0891-5849(03)00062-5

    Article  CAS  PubMed  Google Scholar 

  145. Csiszar A, Wang M, Lakatta EG, Ungvari Z (2008) Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol 105:1333–1341. https://doi.org/10.1152/japplphysiol.90470.2008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Helenius M, Kyrylenko S, Vehviläinen P, Salminen A (2001) Characterization of aging-associated up-regulation of constitutive nuclear factor-kappa B binding activity. Antioxid Redox Signal 3:147–156. https://doi.org/10.1089/152308601750100669

    Article  CAS  PubMed  Google Scholar 

  147. Capiralla H, Vingtdeux V, Zhao H et al (2012) Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem 120:461–472. https://doi.org/10.1111/j.1471-4159.2011.07594.x

    Article  CAS  PubMed  Google Scholar 

  148. Zhong L-M, Zong Y, Sun L et al (2012) Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS ONE 7:e32195. https://doi.org/10.1371/journal.pone.0032195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Jantan I, Haque MA, Arshad L et al (2021) Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways. J Nutr Biochem 93:108634. https://doi.org/10.1016/j.jnutbio.2021.108634

    Article  CAS  PubMed  Google Scholar 

  150. Cianciulli A, Dragone T, Calvello R et al (2015) IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. Int Immunopharmacol 24:369–376. https://doi.org/10.1016/j.intimp.2014.12.035

    Article  CAS  PubMed  Google Scholar 

  151. Song J, Cheon SY, Jung W et al (2014) Resveratrol induces the expression of interleukin-10 and brain-derived neurotrophic factor in BV2 microglia under hypoxia. Int J Mol Sci 15:15512–15529. https://doi.org/10.3390/ijms150915512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Huang J, Huang N, Xu S et al (2021) Signaling mechanisms underlying inhibition of neuroinflammation by resveratrol in neurodegenerative diseases. J Nutr Biochem 88:108552

    Article  CAS  PubMed  Google Scholar 

  153. Talebi M, Talebi M, Kakouri E, et al (2021) Tantalizing role of p53 molecular pathways and its coherent medications in neurodegenerative diseases. Int J Biol Macromol

  154. Donmez G (2012) The effects of SIRT1 on Alzheimer’s disease models. Int J Alzheimer’s Dis 2012:

  155. Y Jia N Wang X Liu 2017 Resveratrol and amyloid-beta: mechanistic insights Nutrients 9.  https://doi.org/10.3390/nu9101122

  156. Li L, Qiu R, Lin Y et al (2018) Resveratrol suppresses human cervical carcinoma cell proliferation and elevates apoptosis via the mitochondrial and p53 signaling pathways. Oncol Lett 15:9845–9851

    PubMed  PubMed Central  Google Scholar 

  157. Dvorakova M, Landa P (2017) Anti-inflammatory activity of natural stilbenoids: a review. Pharmacol Res 124:126–145

    Article  CAS  PubMed  Google Scholar 

  158. Regitz C, Fitzenberger E, Mahn FL et al (2016) Resveratrol reduces amyloid-beta (Aβ1-42)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans. Eur J Nutr 55:741–747. https://doi.org/10.1007/s00394-015-0894-1

    Article  CAS  PubMed  Google Scholar 

  159. Al-Edresi S, Alsalahat I, Freeman S et al (2020) Resveratrol-mediated cleavage of amyloid β(1–42) peptide: potential relevance to Alzheimer’s disease. Neurobiol Aging 94:24–33. https://doi.org/10.1016/j.neurobiolaging.2020.04.012

    Article  CAS  PubMed  Google Scholar 

  160. Al-Bishri WM, Hamza AH, Farran SK (2017) Resveratrol treatment attenuates amyloid beta, tau protein and markers of oxidative stress, and inflammation in Alzheimer’s disease rat model. Int J Pharm Res Allied Sci 6:

  161. Song YM, Ha YM, Kim J-A et al (2012) Synthesis of novel azo-resveratrol, azo-oxyresveratrol and their derivatives as potent tyrosinase inhibitors. Bioorg Med Chem Lett 22:7451–7455

    Article  CAS  PubMed  Google Scholar 

  162. Williams LD, Burdock GA, Edwards JA et al (2009) Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 47:2170–2182

    Article  CAS  PubMed  Google Scholar 

  163. Markus MA, Morris BJ (2008) Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3:331

    CAS  PubMed  PubMed Central  Google Scholar 

  164. Boocock DJ, Faust GES, Patel KR et al (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Prev Biomarkers 16:1246–1252

    Article  CAS  Google Scholar 

  165. Akter A, Islam F, Bepary S, et al (2022) CNS depressant activities of Averrhoa carambola leaves extract in thiopental-sodium model of Swiss albino mice: implication for neuro-modulatory properties. Biologia (Bratisl) 1–10

  166. Rahman MM, Islam F, Anwar Parvez MAK et al (2022) Citrus limon L. (lemon) seed extract shows neuro-modulatory activity in an in vivo thiopental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration. J Integr Neurosci 21:1–9

    Article  Google Scholar 

  167. Burkon A, Somoza V (2008) Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides–two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 52:549–557

    Article  CAS  PubMed  Google Scholar 

  168. Chiang K, Koo EH (2014) Emerging therapeutics for Alzheimer’s disease. Annu Rev Pharmacol Toxicol 54:381–405. https://doi.org/10.1146/annurev-pharmtox-011613-135932

    Article  CAS  PubMed  Google Scholar 

  169. Folch J, Petrov D, Ettcheto M et al (2016) Current research therapeutic strategies for Alzheimer’s Disease treatment. Neural Plast 2016:8501693. https://doi.org/10.1155/2016/8501693

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Dhingra AK, Rathi V, Chopra B (2021) Resveratrol. In: Naturally occurring chemicals against Alzheimer’s disease. Elsevier, pp 33–47

  171. Skretas G, Meligova AK, Villalonga-Barber C et al (2007) Engineered chimeric enzymes as tools for drug discovery: generating reliable bacterial screens for the detection, discovery, and assessment of estrogen receptor modulators. J Am Chem Soc 129:8443–8457. https://doi.org/10.1021/ja067754j

    Article  CAS  PubMed  Google Scholar 

  172. X Kou N Chen 2017 Resveratrol as a natural autophagy regulator for prevention and treatment of Alzheimer’s disease Nutrients 9. https://doi.org/10.3390/nu9090927

  173. Acx H, Serneels L, Radaelli E, et al (2017) Inactivation of γ-secretases leads to accumulation of substrates and non-Alzheimer neurodegeneration. EMBO Mol Med 9:1088–1099. https://doi.org/10.15252/emmm.201707561

  174. Bhattacharjee A, Chakraborty R, Sen S (2021) Plant-based β-secretase (BACE-1) inhibitors: a mechanistic approach to encounter Alzheimer’s disorder. In: factor-kappa validation of traditional medicines. Springer, pp 163–175

  175. Tamagno E, Bardini P, Guglielmotto M et al (2006) The various aggregation states of beta-amyloid 1–42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic Biol Med 41:202–212. https://doi.org/10.1016/j.freeradbiomed.2006.01.021

    Article  CAS  PubMed  Google Scholar 

  176. Ben HS, Mishra S, Raja KMP et al (2016) Specific inhibition of β-secretase processing of the Alzheimer disease amyloid precursor protein. Cell Rep 14:2127–2141

    Article  CAS  Google Scholar 

  177. Oehlrich D, Prokopcova H, Gijsen HJM (2014) The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett 24:2033–2045

    Article  CAS  PubMed  Google Scholar 

  178. Yuan J, Venkatraman S, Zheng Y et al (2013) Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease. J Med Chem 56:4156–4180

    Article  CAS  PubMed  Google Scholar 

  179. Vassar R (2016) BACE1 inhibition as a therapeutic strategy for Alzheimer’s disease. J Sport Heal Sci 5:388

    Article  Google Scholar 

  180. Ghosh AK, Osswald HL (2014) BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev 43:6765–6813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  181. Brodney MA, Beck EM, Butler CR et al (2015) Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug–drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem 58:3223–3252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  182. Barão S, Moechars D, Lichtenthaler SF, De Strooper B (2016) BACE1 physiological functions may limit its use as therapeutic target for Alzheimer’s disease. Trends Neurosci 39:158–169

    Article  PubMed  CAS  Google Scholar 

  183. Busche MA, Hyman BT (2020) Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci 23:1183–1193. https://doi.org/10.1038/s41593-020-0687-6

    Article  CAS  PubMed  Google Scholar 

  184. Trinh TT, Fadriquela A, Bajgai J, et al (2021) Anti-oxidative effect of weak alkaline reduced water in raw 264.7 murine macrophage cells. Processes 9:. https://doi.org/10.3390/pr9112062

  185. Kesidou E, Lagoudaki R, Touloumi O et al (2013) Autophagy and neurodegenerative disorders. Neural Regen Res 8:2275–2283. https://doi.org/10.3969/j.issn.1673-5374.2013.24.007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. M Grover T Behl M Sanduja et al 2021 Exploring the potential of Aromatherapy as an Adjuvant Therapy in Cancer and its Complications: A Comprehensive Update Anticancer Agents Med Chem 21https://doi.org/10.2174/1871520621666210204201937

  187. Sindhu RK, Najda A, Kaur P, et al (2021) Potentiality of nanoenzymes for cancer treatment and other diseases: current status and future challenges. Materials (Basel). 14

  188. He Q, Li Z, Wang Y et al (2017) Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasome activation through Sirt1-dependent autophagy induction. Int Immunopharmacol 50:208–215. https://doi.org/10.1016/j.intimp.2017.06.029

    Article  CAS  PubMed  Google Scholar 

  189. Yang Y, Zhang L (2020) The effects of caloric restriction and its mimetics in Alzheimer’s disease through autophagy pathways. Food Funct 11:1211–1224. https://doi.org/10.1039/c9fo02611h

    Article  CAS  PubMed  Google Scholar 

  190. Deng H, Mi M-T (2016) Resveratrol attenuates Aβ25-35 caused neurotoxicity by inducing autophagy through the TyrRS-PARP1-SIRT1 signaling pathway. Neurochem Res 41:2367–2379. https://doi.org/10.1007/s11064-016-1950-9

    Article  CAS  PubMed  Google Scholar 

  191. Akter R, Najda A, Rahman MH, et al (2021) Potential role of natural products to combat radiotherapy and their future perspectives. Molecules 26

  192. Jeong J-K, Moon M-H, Bae B-C et al (2012) Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. Neurosci Res 73:99–105. https://doi.org/10.1016/j.neures.2012.03.005

    Article  CAS  PubMed  Google Scholar 

  193. Akter R, Rahman MH, Kaushik D, et al (2021) Chemo-preventive action of resveratrol: Suppression of p53—a molecular targeting approach. Molecules 26

  194. Pourhanifeh MH, Shafabakhsh R, Reiter RJ, Asemi Z (2019) The effect of resveratrol on neurodegenerative disorders: possible protective actions against autophagy, apoptosis, inflammation and oxidative stress. Curr Pharm Des 25:2178–2191. https://doi.org/10.2174/1381612825666190717110932

    Article  CAS  PubMed  Google Scholar 

  195. Rahman MA, Rahman MH, Hossain MS, et al (2020) Molecular insights into the multifunctional role of natural compounds: Autophagy modulation and cancer prevention. Biomedicines 8

  196. Armour SM, Baur JA, Hsieh SN, et al (2009) Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 1:515–528. https://doi.org/10.18632/aging.100056

  197. Ahsan AU, Sharma VL, Wani A, Chopra M (2020) Naringenin upregulates AMPK-mediated autophagy to rescue neuronal cells from β-amyloid ((1–42)) evoked neurotoxicity. Mol Neurobiol 57:3589–3602. https://doi.org/10.1007/s12035-020-01969-4

    Article  CAS  PubMed  Google Scholar 

  198. Lu C, Xing H, Yang L et al (2021) Resveratrol ameliorates high-fat-diet-induced abnormalities in hepatic glucose metabolism in mice via the AMP-activated protein kinase pathway. Evid Based Complement Alternat Med 2021:6616906. https://doi.org/10.1155/2021/6616906

    Article  PubMed  PubMed Central  Google Scholar 

  199. Wang S-F, Wu M-Y, Cai C-Z et al (2016) Autophagy modulators from traditional Chinese medicine: mechanisms and therapeutic potentials for cancer and neurodegenerative diseases. J Ethnopharmacol 194:861–876. https://doi.org/10.1016/j.jep.2016.10.069

    Article  CAS  PubMed  Google Scholar 

  200. Yang J-S, Lu C-C, Kuo S-C et al (2017) Autophagy and its link to type II diabetes mellitus. Biomedicine 7:8. https://doi.org/10.1051/bmdcn/2017070201

    Article  PubMed  PubMed Central  Google Scholar 

  201. Bonkowski MS, Sinclair DA (2016) Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds. Nat Rev Mol Cell Biol 17:679–690. https://doi.org/10.1038/nrm.2016.93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Sinclair DA, Guarente L (2014) Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol 54:363–380. https://doi.org/10.1146/annurev-pharmtox-010611-134657

    Article  CAS  PubMed  Google Scholar 

  203. Tarantini S, Yabluchanskiy A, Csipo T et al (2019) Treatment with the poly(ADP-ribose) polymerase inhibitor PJ-34 improves cerebromicrovascular endothelial function, neurovascular coupling responses and cognitive performance in aged mice, supporting the NAD+ depletion hypothesis of neurovascular aging. GeroScience 41:533–542. https://doi.org/10.1007/s11357-019-00101-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Sarubbo F, Esteban S, Miralles A, Moranta D (2018) Effects of resveratrol and other polyphenols on Sirt1: relevance to brain function during aging. Curr Neuropharmacol 16:126–136. https://doi.org/10.2174/1570159X15666170703113212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Cummings J, Fox N, Vellas B, et al (2018) Biomarker and clinical trial design support for disease-modifying therapies: report of a survey of the EU/US: Alzheimer’s disease Task Force. J Prev Alzheimer’s Dis 5:103–109. https://doi.org/10.14283/jpad.2018.13

  206. Wang Z, Guo W, Yi F et al (2021) The regulatory effect of SIRT1 on extracellular microenvironment remodeling. Int J Biol Sci 17:89–96. https://doi.org/10.7150/ijbs.52619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  207. Heinonen T, Ciarlo E, Rigoni E et al (2019) Dual deletion of the sirtuins SIRT2 and SIRT3 impacts on metabolism and inflammatory responses of macrophages and protects from endotoxemia. Front Immunol 10:2713. https://doi.org/10.3389/fimmu.2019.02713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Zhou F, Zhang L, Zhu K et al (2021) SIRT2 ablation inhibits glucose-stimulated insulin secretion through decreasing glycolytic flux. Theranostics 11:4825–4838. https://doi.org/10.7150/thno.55330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. Lan F, Lin Y, Gao Z, et al (2020) Activation of LKB1 rescues 3T3-L1 adipocytes from senescence induced by Sirt1 knock-down: a pivotal role of LKB1 in cellular aging. Aging (Albany NY) 12:18942–18956. https://doi.org/10.18632/aging.104052

  210. Qadir MI, Anwar S (2017) Sirtuins in brain aging and neurological disorders. Crit Rev Eukaryot Gene Expr 27:321–329. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017019532

    Article  PubMed  Google Scholar 

  211. Chandramowlishwaran P, Vijay A, Abraham D et al (2020) Role of sirtuins in modulating neurodegeneration of the enteric nervous system and central nervous system. Front Neurosci 14:614331. https://doi.org/10.3389/fnins.2020.614331

    Article  PubMed  PubMed Central  Google Scholar 

  212. Rizzi L, Roriz-Cruz M (2018) Sirtuin 1 and Alzheimer’s disease: an up-to-date review. Neuropeptides 71:54–60. https://doi.org/10.1016/j.npep.2018.07.001

    Article  CAS  PubMed  Google Scholar 

  213. Mayo S, Benito-León J, Peña-Bautista C et al (2021) Recent evidence in epigenomics and proteomics biomarkers for early and minimally invasive diagnosis of Alzheimer’s and Parkinson’s diseases. Curr Neuropharmacol 19:1273–1303. https://doi.org/10.2174/1570159X19666201223154009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Mahady L, Nadeem M, Malek-Ahmadi M et al (2018) Frontal cortex epigenetic dysregulation during the progression of Alzheimer’s disease. J Alzheimers Dis 62:115–131. https://doi.org/10.3233/JAD-171032

    Article  CAS  PubMed  Google Scholar 

  215. Myers RW, Guan H-P, Ehrhart J et al (2017) Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 357:507–511. https://doi.org/10.1126/science.aah5582

    Article  CAS  PubMed  Google Scholar 

  216. Y-T Lin Y-C Wu G-C Sun et al 2018 Effect of resveratrol on reactive oxygen species-induced cognitive impairment in rats with angiotensin II-induced early Alzheimer’s disease (†) J Clin Med 7https://doi.org/10.3390/jcm7100329

  217. Yeh T-C, Shin C-S, Chen H-H et al (2018) Resveratrol regulates blood pressure by enhancing AMPK signaling to downregulate a Rac1-derived NADPH oxidase in the central nervous system. J Appl Physiol 125:40–48. https://doi.org/10.1152/japplphysiol.00686.2017

    Article  CAS  PubMed  Google Scholar 

  218. Yeh Y-C, Li C-W, Kuo Y-T et al (2018) Association between altered neurochemical metabolites and apathy in patients with Alzheimer’s disease. Int psychogeriatrics 30:761–768. https://doi.org/10.1017/S1041610217002381

    Article  Google Scholar 

  219. Yang H, Huang F, Tao Y et al (2017) Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in mice. Int J Mol Med 40:762–770. https://doi.org/10.3892/ijmm.2017.3047

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  220. Lin C-C, Wang H-Y, Liaw S-F et al (2019) Effect of oral appliance on circulating leukocyte telomere length and SIRT1 in obstructive sleep apnea. Clin Oral Investig 23:1397–1405. https://doi.org/10.1007/s00784-018-2560-5

    Article  PubMed  Google Scholar 

  221. Udomruk S, Kaewmool C, Phitak T et al (2020) Sesamin promotes neurite outgrowth under insufficient nerve growth factor condition in PC12 cells through ERK1/2 pathway and SIRT1 modulation. Evid Based Complement Alternat Med 2020:9145458. https://doi.org/10.1155/2020/9145458

    Article  PubMed  PubMed Central  Google Scholar 

  222. Zahedi H, Hedayati M (2018) The effect of 14 weeks aerobic exercise on resveratrol supplementation on protein UCP-1, SIRT1, PGC-1α in liver tissue, subcutaneous and visceral fat tissue in male wistar rats. J Sport Biosci 10:39–58

    Google Scholar 

  223. Li X, Yang S, Wang L et al (2019) Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1α pathway. J Pain Res 12:879–890. https://doi.org/10.2147/JPR.S185873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  224. Hatsukano T, Kurisu J, Fukumitsu K et al (2017) Thyroid hormone induces PGC-1α during dendritic outgrowth in mouse cerebellar Purkinje cells. Front Cell Neurosci 11:133. https://doi.org/10.3389/fncel.2017.00133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  225. Li C, Wang F, Miao P et al (2020) miR-138 increases depressive-like behaviors by targeting SIRT1 in hippocampus. Neuropsychiatr Dis Treat 16:949–957. https://doi.org/10.2147/NDT.S237558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  226. Sethi S (2018) The developmental neurotoxicity of 3, 3&vprime;-dichlorobiphenyl (PCB 11)

  227. Fujita Y, Yamashita T (2018) Sirtuins in neuroendocrine regulation and neurological diseases. Front Neurosci 12:778. https://doi.org/10.3389/fnins.2018.00778

    Article  PubMed  PubMed Central  Google Scholar 

  228. Kuno A, Hosoda R, Sebori R et al (2018) Resveratrol ameliorates mitophagy disturbance and improves cardiac pathophysiology of dystrophin-deficient mdx mice. Sci Rep 8:15555. https://doi.org/10.1038/s41598-018-33930-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  229. T Konno EP Melo JE Chambers E Avezov 2021 Intracellular Sources of ROS/H(2)O(2) in Health and neurodegeneration: spotlight on endoplasmic reticulum Cells 10https://doi.org/10.3390/cells10020233

  230. Freyssin A, Page G, Fauconneau B, Rioux Bilan A (2020) Natural stilbenes effects in animal models of Alzheimer’s disease. Neural Regen Res 15:843–849. https://doi.org/10.4103/1673-5374.268970

    Article  PubMed  Google Scholar 

  231. Vion E, Page G, Bourdeaud E et al (2018) Trans ε-viniferin is an amyloid-β disaggregating and anti-inflammatory drug in a mouse primary cellular model of Alzheimer’s disease. Mol Cell Neurosci 88:1–6. https://doi.org/10.1016/j.mcn.2017.12.003

    Article  CAS  PubMed  Google Scholar 

  232. Cicero AFG, Ruscica M, Banach M (2019) Resveratrol and cognitive decline: a clinician perspective. Arch Med Sci 15:936–943. https://doi.org/10.5114/aoms.2019.85463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  233. Chan EWC, Wong CW, Tan YH et al (2019) Resveratrol and pterostilbene: a comparative overview of their chemistry, biosynthesis, plant sources and pharmacological properties. J Appl Pharm Sci 9:124–129

    Article  CAS  Google Scholar 

  234. SC Baraban 2021 A zebrafish-centric approach to antiepileptic drug development Dis Model Mech 14. https://doi.org/10.1242/dmm.049080

  235. Lin H-S, Yue B-D, Ho PC (2009) Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed Chromatogr 23:1308–1315. https://doi.org/10.1002/bmc.1254

    Article  CAS  PubMed  Google Scholar 

  236. Lange KW, Li S (2018) Resveratrol, pterostilbene, and dementia. BioFactors 44:83–90. https://doi.org/10.1002/biof.1396

    Article  CAS  PubMed  Google Scholar 

  237. Cichocki M, Paluszczak J, Szaefer H et al (2008) Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFkappaB, AP-1, COX-2, and iNOS in mouse epidermis. Mol Nutr Food Res 52(Suppl 1):S62-70. https://doi.org/10.1002/mnfr.200700466

    Article  PubMed  Google Scholar 

  238. Wang P, Sang S (2018) Metabolism and pharmacokinetics of resveratrol and pterostilbene. BioFactors 44:16–25. https://doi.org/10.1002/biof.1410

    Article  CAS  PubMed  Google Scholar 

  239. Song Z, Han S, Pan X et al (2015) Pterostilbene mediates neuroprotection against oxidative toxicity via oestrogen receptor α signalling pathways. J Pharm Pharmacol 67:720–730. https://doi.org/10.1111/jphp.12360

    Article  CAS  PubMed  Google Scholar 

  240. Yang Y, Fan C, Wang B et al (2017) Pterostilbene attenuates high glucose-induced oxidative injury in hippocampal neuronal cells by activating nuclear factor erythroid 2-related factor 2. Biochim Biophys acta Mol basis Dis 1863:827–837. https://doi.org/10.1016/j.bbadis.2017.01.005

    Article  CAS  PubMed  Google Scholar 

  241. Li Q, Chen L, Liu X et al (2018) Pterostilbene inhibits amyloid-β-induced neuroinflammation in a microglia cell line by inactivating the NLRP3/caspase-1 inflammasome pathway. J Cell Biochem 119:7053–7062. https://doi.org/10.1002/jcb.27023

    Article  CAS  PubMed  Google Scholar 

  242. Tagde P, Tagde P, Islam F et al (2021) The multifaceted role of curcumin in advanced nanocurcumin form in the treatment and management of chronic disorders. Molecules 26:7109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Rahman M, Islam F, Afsana Mim S, et al (2022) Multifunctional therapeutic approach of nanomedicines against inflammation in cancer and aging. J Nanomater 2022:

  244. Chopra H, Bibi S, Islam F, et al (2022) Emerging trends in the delivery of resveratrol by nanostructures: applications of nanotechnology in life sciences. J Nanomater 2022:

  245. Chang J, Rimando A, Pallas M et al (2012) Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer’s disease. Neurobiol Aging 33:2062–2071. https://doi.org/10.1016/j.neurobiolaging.2011.08.015

    Article  CAS  PubMed  Google Scholar 

  246. Hou Y, Xie G, Miao F et al (2014) Pterostilbene attenuates lipopolysaccharide-induced learning and memory impairment possibly via inhibiting microglia activation and protecting neuronal injury in mice. Prog Neuropsychopharmacol Biol Psychiatry 54:92–102. https://doi.org/10.1016/j.pnpbp.2014.03.015

    Article  CAS  PubMed  Google Scholar 

  247. Puksasook T, Kimura S, Tadtong S et al (2017) Semisynthesis and biological evaluation of prenylated resveratrol derivatives as multi-targeted agents for Alzheimer’s disease. J Nat Med 71:665–682. https://doi.org/10.1007/s11418-017-1097-2

    Article  CAS  PubMed  Google Scholar 

  248. Oberdorff T, Dias MS, Jézéquel C, et al (2019) Unexpected fish diversity gradients in the Amazon basin. Sci Adv 5:eaav8681. https://doi.org/10.1126/sciadv.aav8681

  249. Zhang Y, Zhang L-H, Chen X et al (2018) Piceatannol attenuates behavioral disorder and neurological deficits in aging mice via activating the Nrf2 pathway. Food Funct 9:371–378. https://doi.org/10.1039/c7fo01511a

    Article  CAS  PubMed  Google Scholar 

  250. Son Y, Byun SJ, Pae H-O (2013) Involvement of heme oxygenase-1 expression in neuroprotection by piceatannol, a natural analog and a metabolite of resveratrol, against glutamate-mediated oxidative injury in HT22 neuronal cells. Amino Acids 45:393–401. https://doi.org/10.1007/s00726-013-1518-9

    Article  CAS  PubMed  Google Scholar 

  251. Manjula R, Anuja K, Alcain FJ (2020) SIRT1 and SIRT2 activity control in neurodegenerative diseases. Front Pharmacol 11:585821. https://doi.org/10.3389/fphar.2020.585821

    Article  CAS  PubMed  Google Scholar 

  252. Peñalver P, Belmonte-Reche E, Adán N et al (2018) Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases. Eur J Med Chem 146:123–138

    Article  PubMed  CAS  Google Scholar 

  253. Tang Y-W, Shi C-J, Yang H-L et al (2019) Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer’s disease. Eur J Med Chem 163:307–319

    Article  CAS  PubMed  Google Scholar 

  254. Di Mauro TM (2010) Curcumin-resveratrol hybrid molecule. US7745670

  255. Van Der Beek EM, De Wilde MC, Groenendijk M, Kamphuis PJGH (2010) Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning

  256. Pezzuto JM, Kondratyuk TP, Ogas T (2013) Resveratrol derivatives: a patent review (2009–2012). Expert Opin Ther Pat 23:1529–1546

    Article  CAS  PubMed  Google Scholar 

  257. Vercauteren J (2010) Compositions comprising stilbene polyphenol derivatives and use thereof for combating the ageing of living organisms and diseases affecting same

  258. Lephart ED, Andrus MB (2013) Methods for providing enhanced resveratrol activity using 4-acetoxy-resveratrol

  259. Sinclair DA, Tsai L-H, Fischer A (2016) Cognitive performance with sirtuin activators

  260. Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215:9–15. https://doi.org/10.1111/j.1749-6632.2010.05842.x

    Article  CAS  PubMed  Google Scholar 

  261. Cottart C-H, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux J-L (2010) Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54:7–16. https://doi.org/10.1002/mnfr.200900437

    Article  CAS  PubMed  Google Scholar 

  262. Nunes T, Almeida L, Rocha J-F et al (2009) Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 49:1477–1482. https://doi.org/10.1177/0091270009339191

    Article  CAS  PubMed  Google Scholar 

  263. Amiot MJ, Romier B, Dao T-MA et al (2013) Optimization of trans-resveratrol bioavailability for human therapy. Biochimie 95:1233–1238. https://doi.org/10.1016/j.biochi.2013.01.008

    Article  CAS  PubMed  Google Scholar 

  264. Mecocci P, Polidori MC (2012) Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta 1822:631–638. https://doi.org/10.1016/j.bbadis.2011.10.006

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This publication was supported by the Deanship of Scientific Research at Prince Sattam Bin Abdelaziz University, Al-Kharj, Saudi Arabia as well as the authors are sincerely grateful to Egyptian Russian University, Badr, Egypt for its support.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, 1207, Bangladesh

    Fahadul Islam, Md. Rezaul Islam, Susmita Saha, Salma Rashid, Aklima Akter & Md. Harun- Or-Rashid

  2. Faculty of Applied Health Science Technology, Misr University for Science and Technology, Giza, Egypt

    Mohamed H. Nafady

  3. Riphah Institute of Pharmaceutical Sciences, Riphah International University Lahore Campus, Lahore, Pakistan

    Muhammad Furqan Akhtar

  4. Glocal School of Life Sciences, Glocal University, Uttar Pradesh, Mirzapur Pole, Saharanpur, India

    Asma Perveen

  5. Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia

    Ghulam Md. Ashraf

  6. Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia

    Ghulam Md. Ashraf

  7. Department of Pharmacy, Southeast University, Banani, Dhaka, 1213, Bangladesh

    Md. Habibur Rahman

  8. Department of Global Medical Science, Wonju College of Medicine, Yonsei University, Gangwon-do, Wonju, 26426, South Korea

    Md. Habibur Rahman

  9. Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia

    Sherouk Hussein Sweilam

  10. Department of Pharmacognosy, Faculty of Pharmacy, Egyptian Russian University, Cairo-Suez Road, Badr City 11829, Egypt

    Sherouk Hussein Sweilam

Authors
  1. Fahadul Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed H. Nafady
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Md. Rezaul Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susmita Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Salma Rashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aklima Akter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Md. Harun- Or-Rashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Muhammad Furqan Akhtar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Asma Perveen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ghulam Md. Ashraf
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Md. Habibur Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sherouk Hussein Sweilam
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Fahadul Islam: conceptualization, writing—review and editing, writing original draft, Mohamed H. Nafady, Md. Rezaul Islam, Susmita Saha, Salma Rashid, Aklima Akter, Md. Harun-Or-Rashid, Muhammad Furqan Akhtar, writing—review, and editing, Md. Habibur Rahman and Ghulam Md. Ashraf: writing—review and editing, and supervision. Sherouk Hussein Sweilam, conceptualization, review and editing, and supervision.

Corresponding author

Correspondence to Sherouk Hussein Sweilam.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Islam, F., Nafady, M.H., Islam, M. et al. Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer’s disease from bench to bedside. Mol Neurobiol 59, 4384–4404 (2022). https://doi.org/10.1007/s12035-022-02859-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-022-02859-7

Keywords

Search

Navigation